FDA Investigator Sarah Arden

Sarah Arden has conducted inspections on 2 sites in 2 countries as of 17 Jul 2017. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
2
Last Inspection Date:
17 Jul 2017
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Korea (Republic of), United States of America
FDA Investigators that have inspected at least one site in common with Sarah Arden:
Alicia M Mozzachio, Amalia C Himaya, Anita Narula, PhD, Barry Cherney, PhD, Bichsa T Tran, Bo Chi, PhD, Brien C Fox, Carla J Lundi, Caryn M Mcnab, Cheron M Portee, Christina C Santos, Christina V Santos, Daniel W Cline, Davinna Ligons, PhD, Deborah Schmiel, PhD, Diane Cvan Leeuwen, Diane L Raccasi, Doan T Nguyen, PharmD, Dogbeda F Mackenzie, Donna Ltartaglino Besone, Dr. Ralph M Bernstein, PhD, Esther C Broner, PhD, Frances Namuswe, PhD, Haley H Seymour, Haroon Vohra (NMI), Hasan A Irier, PhD, Hyung Yul Lee, Iris C Macinnes, Jacek Cieslak, PhD, James R Fleckenstein, Jee Chung, PhD, Jeffrey P Raimondi, Jennifer Gogley, Jennifer M Gogley, Joel Welch, PhD, John R Myung, Junho Pak, Ka L Wong, Kathleen R Jones, PhD, Kelvin Cheung, Kelvin X Sanders, Kendra A Biddick, Kim Lthomas Cruse, Laura Fontan, MS, Laurel A Beer, Leonard H Lavi, Lucila B Nwatu, Madushini Dharmasena, PhD, Marcia B Williams, Marcus F Yambot, Maria Gutierrez Lugo, PhD, Maria Joselopez Barragan, PhD, Marion Michaelis, Matthew B Casale, Maxyne T Lam, Michael Shanks, MS, Michelle A Marsh, Mihaly S Ligmond, Mohsen Rajabi Abhari, FDA, Monica Markovski, PhD, Nicholas Obiri, PhD, Nicola M Fenty Stewart, Omotunde O Osunsanmi, Patrick J Lynch, Peter S Diak, Phillip Angart, PhD, Prabhu P Raju, Rebecca Rodriguez, Reyes Candau Chacon, PhD, Richmond K Yip, Riley C Myers, PhD, Robert D Tollefsen, Robert Darius, Roger F Zabinski, Rona Leblanc, PhD, Ronald L Koller, Ronda Leblanc, Sarah Kennett, PhD, Scott R Nichols, PhD, Sidney B Priesmeyer, Sonia R Peterson, Stanley Au, Steven Fong, MS, PhD, Taichun Qin, PhD, Tamika White, Terri L Dodds, Thao T Kwan, Thao X Tran, Thuy T Nguyen, LCDR, Uttaniti Limchumroon (Tom), Virginia Carroll, PhD, Wayne E Seifert, Yumi J Hiramine, Yun Wu, PhD, Yvonne C Wilkes, Zhong Li, PhD

Sarah Arden's Documents

Publish Date Document Type Title
July, 2017 FDA 483 Samsung Biologics Co., Ltd. - Form 483, 2017-07-25
May, 2017 FDA 483 Amgen, Inc - Form 483, 2017-05-16

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more